TBIQYR7547-Global Biosimilar Monoclonal Antibodies Market Research Report 2019

                                          
Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.
Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.
The classification of Biosimilar Monoclonal Antibodies includes Infliximab, Rituximab, Trastuzumab, Adalimumab and Other, and the sales proportion of Infliximab in 2017 is about 36.5%, and the proportion is increasing trend from 2013 to 2018.
Biosimilar Monoclonal Antibodies is widely used for Oncology, Autoimmune Disease and Others. The most proportion of Biosimilar Monoclonal Antibodies is sales in Autoimmune Disease, and the consumption proportion is about 85.6% in 2017.
Europe is the largest consumption place, with a revenue market share nearly 51.4% in 2017. Following Europe, North America is the second largest consumption place with the revenue market share of 26.2%, China is also an important sales region for the Biosimilar Monoclonal Antibodies.

The global Biosimilar Monoclonal Antibodies market is valued at 1510 million US$ in 2018 is expected to reach 15200 million US$ by the end of 2025, growing at a CAGR of 33.5% during 2019-2025.
This report focuses on Biosimilar Monoclonal Antibodies volume and value at global level, regional level and company level. From a global perspective, this report represents overall Biosimilar Monoclonal Antibodies market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
    Celltrion
    Pfizer (Hospira)
    3SBIO
    Novartis (Sandoz)
    Dr Reddy’s
    Celgen Biopharma
    Cadila Healthcare
    Hisun Pharma
    Torrent Pharmaceuticals

Segment by Regions
    North America
    Europe
    China
    Japan

Segment by Type
    Infliximab
    Rituximab
    Trastuzumab
    Adalimumab
    Other

Segment by Application
    Oncology
    Autoimmune Disease
    Other